Ting Xu

5.5k total citations · 1 hit paper
175 papers, 3.6k citations indexed

About

Ting Xu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Ting Xu has authored 175 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Oncology, 65 papers in Pulmonary and Respiratory Medicine and 55 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Ting Xu's work include Cancer Immunotherapy and Biomarkers (38 papers), Lung Cancer Diagnosis and Treatment (28 papers) and Effects of Radiation Exposure (22 papers). Ting Xu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (38 papers), Lung Cancer Diagnosis and Treatment (28 papers) and Effects of Radiation Exposure (22 papers). Ting Xu collaborates with scholars based in China, United States and Italy. Ting Xu's co-authors include Zhongxing Liao, Shaojing Zhao, Minhuan Lan, Huang Li, Changwei Lin, Xiuli Zheng, Daniel R. Gomez, Radhe Mohan, Xiaoxiao Wang and Xuejian Xing and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ting Xu

166 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Advances and perspectives in organic sonosensitizers for sonodynamic therapy

2021 259 citations Ting Xu et al. profile →

Peers

Countries citing papers authored by Ting Xu

Since Specialization

Citations

This map shows the geographic impact of Ting Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ting Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ting Xu more than expected).

Fields of papers citing papers by Ting Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ting Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ting Xu. The network helps show where Ting Xu may publish in the future.

Co-authorship network of co-authors of Ting Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Ting Xu. A scholar is included among the top collaborators of Ting Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ting Xu. Ting Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multiomic based Bayesian network toxicity modeling for simultaneous prediction of multiple toxicity outcomes in NSCLC 2025 ·Radiotherapy and Oncology ·(unknown), (unknown), Ting Xu, (unknown), Zhongxing Liao, Laurence E. Court, (unknown)	0
2	A biparatopic HER2-targeting ADC constructed via site-specific glycan conjugation exhibits superior stability, safety, and efficacy 2025 ·RSC Chemical Biology ·(unknown), (unknown), Wenkui Dai, Qingsong Wu, (unknown), (unknown), (unknown), Yang Yang, Wenhao Yu, Siyang Liu, Ting Xu, Jie Li	1
3	CG001, a C3b-targeted complement inhibitor, blocks 3 complement pathways: development and preclinical evaluation 2024 ·Blood Advances ·Ling Li, Peipei Ding, Yanrong Dong, (unknown), Xinyue Lv, (unknown), Luying Li, Jianfeng Chen, Pilin Wang, Bing Han, Ting Xu, Weiguo Hu	3
4	MET amplification correlates with poor prognosis and immunotherapy response as a subtype of melanoma: a multicenter retrospective study 2024 ·BMC Cancer ·Xiaojun Cai, Jing Lin, Caili Li, Ting Xu, Chuanben Chen, (unknown), Xuefeng Wang, (unknown), Yu-Fang Huang, Huishan Zhang, Lu Si, Yu Chen	0
5	Impact of cancer therapy on clonal hematopoiesis mutations and subsequent clinical outcomes 2024 ·Blood Advances ·Kevin T. Nead, Tae‐Beom Kim, (unknown), (unknown), (unknown), (unknown), (unknown), Jing Zhao, Ting Xu, Chad Tang, Chang‐Lung Lee, Jun‐ichi Abe, Kelly L. Bolton, Zhongxing Liao, Paul Scheet, Steven H. Lin	9
6	Proton Sponge Nanocomposites for Synergistic Tumor Elimination via Autophagy Inhibition-Promoted Cell Apoptosis and Macrophage Repolarization-Enhanced Immune Response 2024 ·ACS Applied Materials & Interfaces ·Yifan Duan, Wei Zhang, Yi Ouyang, Qiang Yang, Qiuye Zhang, (unknown), Sheng Zhao, Chunmei Chen, Ting Xu, Qun Zhang, Haitao Ran, Hui Liu	10
7	Comorbidities and Their Impact on Treatment Tolerance and Outcome in Elderly NSCLC Patients Treated with Concurrent Chemoradiation Using Proton or Photon Followed by Immunotherapy 2023 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), Ting Xu, (unknown), Ajay Sheshadri, Anita Deswal, (unknown), (unknown), Tina Cascone, Xiuning Le, Mehmet Altan, (unknown), Zhongxing Liao	1
8	Facile Synthesis of Basic Copper Carbonate Nanosheets for Photoacoustic Imaging-Guided Tumor Apoptosis and Ferroptosis and the Extension Exploration of the Synthesis Method 2023 ·ACS Applied Materials & Interfaces ·Sheng Zhao, Jianxin Wang, Shiyu Lu, Jingjing Wang, (unknown), (unknown), Ting Xu, Yanqing Liu, (unknown), Chunmei Chen, Yi Ouyang, (unknown), Yan Chen, (unknown), Yang Cao, Hui Liu	3
9	Efficacy and safety of agomelatine in the treatment of patients with depressive disorder: A meta-analysis 2023 ·Medicine ·(unknown), (unknown), (unknown), Wang Jian, Lei Zhang, Ting Xu, (unknown), (unknown)	3
10	Radiation-Induced Esophagitis in Non-Small-Cell Lung Cancer Patients: Voxel-Based Analysis and NTCP Modeling 2022 ·Cancers ·Serena Monti, Ting Xu, Radhe Mohan, Zhongxing Liao, Giuseppe Palma, Laura Cella	21
11	1022P A phase II study of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer (NSCLC) who failed first line treatment 2022 ·Annals of Oncology ·Caicun Zhou, (unknown), Jian Fang, (unknown), Yong Fan, Wei Zhuang, Qi Xie, Zhi Ma, Mafei Kang, Ting Xu, (unknown), (unknown), (unknown), H. Wang	3
12	Probing thoracic dose patterns associated to pericardial effusion and mortality in patients treated with photons and protons for locally advanced non-small-cell lung cancer 2021 ·Radiotherapy and Oncology ·Laura Cella, Serena Monti, Ting Xu, Raffaele Liuzzi, Arnaldo Stanzione, Marco Durante, Radhe Mohan, Zhongxing Liao, Giuseppe Palma	13
13	Development and application of an elastic net logistic regression model to investigate the impact of cardiac substructure dose on radiation-induced pericardial effusion in patients with NSCLC 2020 ·Acta Oncologica ·(unknown), Wei Xiong, Ting Xu, Daniel R. Gomez, Zhongxing Liao, James A. Bankson, Stephen Y. Lai, Laurence E. Court, Jinzhong Yang	7
14	Construction of an Immune-Associated Gene-Based Signature in Muscle-Invasive Bladder Cancer 2020 ·Disease Markers ·(unknown), Ting Xu, (unknown), Liping Wang, Zhijuan Liang, (unknown), Wei Jiao, Yonghua Wang	8
15	810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors 2020 ·SHILAP Revista de lepidopterología ·Jifang Gong, Lin Shen, (unknown), Dan Liu, June Xu, Jing Yang, Yue Yang, (unknown), (unknown), (unknown), Ting Xu	4
16	Targeting SREBP1 chemosensitizes colorectal cancer cells to gemcitabine by caspase-7 upregulation 2019 ·Bioengineered ·(unknown), Ting Xu, Dong Chen, Xiaojie Tan	24
17	Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance 2018 ·Molecular Cancer Therapeutics ·Zhipeng Su, (unknown), (unknown), (unknown), Ting Xu, Wei Xie, Xing Huang	17
18	Sequential Tracking of PD-L1 Expression and RAD50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy 2017 ·Clinical Cancer Research ·Daniel L. Adams, Diane K. Adams, Jianzhong He, Neda Kalhor, Ming Zhang, Ting Xu, Hui Gao, James M. Reuben, Yawei Qiao, Ritsuko Komaki, Zhongxing Liao, Martin J. Edelman, Cha-Mei Tang, Steven H. Lin	80
19	A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity 2016 ·International Immunopharmacology ·Yan Luan, Dafei Chai, (unknown), (unknown), Min Wang, Hui Ma, (unknown), (unknown), (unknown), Xiaoxiao Wang, Songbing Qin, Ting Xu	14
20	Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression 2016 ·Oncogene ·Yunbao Pan, Sumei Wang, Bing Su, Fuling Zhou, (unknown), Ting Xu, (unknown), Vasiliki Leventaki, Ηλίας Δράκος, Wenru Liu, François X. Claret	50

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact